RecruitingPhase 4NCT06046859

Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma?


Sponsor

University of Florida

Enrollment

200 participants

Start Date

Mar 1, 2024

Study Type

INTERVENTIONAL

Summary

With this prospective double-blinded, placebo controlled clinical trial we hypothesize that immediate (post-injury) intervention with Fluoxetine will prevent/mitigate the development of negative psychiatric symptomology such as PTSD and depression for victims of bodily trauma. We also hypothesize that immediate use of Fluoxetine will decrease subjects' pain, pain interference and opioid use without changing our standard of care post-injury pain medication regimen. Enrolled subjects will be randomized to Fluoxetine or placebo at their index hospitalization.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria5

  • Admitted to UF Health for trauma resulting in:
  • One or more extremity fractures requiring surgery
  • Pelvic Fracture
  • Chest/abdominal Injury requiring intervention in operating room
  • Polytrauma (multiple organ systems/multiple fractures) or Beck Depression Inventory (BDI-II) ≥ 14

Exclusion Criteria7

  • Severe Traumatic Brain Injury or cognitively not able to participate in surveys. (Glasgow Coma Scale 3-8)
  • Other psychiatric conditions on current medical management (SSRI)
  • Incarceration or Pregnancy
  • Expected Injury Survival of less than 90 days
  • Medical or physical condition in opinion of investigators that would preclude safe study participation
  • Unable to provide informed consent due to language or other barriers
  • Current or previous substance abuse (excluding cannabinoids and alcohol)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFluoxetine

Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits

DRUGPlacebo

When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine


Locations(1)

University of Florida

Gainesville, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06046859